3 Controlled-Substance Handling and Pharmacy Operations

Federal framework and schedules

The Controlled Substances Act (CSA) and DEA regulations establish an accountability system for pharmacies. Pharmacies must be authorized to handle controlled drugs, secure them, document their movement, and respond appropriately to shortages or unwanted stock. State pharmacy and controlled-substance laws may add requirements or impose stricter ones, so federal compliance alone may not be sufficient.

Schedules and product-specific rules

The CSA places controlled substances in Schedules I–V according to factors that include accepted medical use and potential for abuse and dependence. Schedule I substances are not considered to have an accepted medical use under federal law and are not part of routine community-pharmacy dispensing. Schedules II–V include drugs with accepted medical uses and decreasing relative abuse potential across the schedules.

Pharmacy rules vary by schedule. Schedule II records have distinct filing requirements, and orders for Schedule I and II substances generally require a DEA Form 222 or its electronic equivalent.

A REMS is an FDA drug-safety program, not a DEA schedule. If a drug’s REMS requires pharmacy certification, special documentation, or dispensing only to eligible patients or settings, the pharmacy must follow those product-specific conditions as well as ordinary controlled-substance requirements.

Registration and authorized locations

A pharmacy that dispenses controlled substances generally must hold an active DEA registration and the appropriate state authority. A separate DEA registration is generally required for each principal place of business where controlled substances are dispensed. The pharmacy may handle only the schedules and activities authorized by its registration.

Keep registration details current, and confirm that ordering suppliers and transfer recipients are appropriately registered. Registration requirements are summarized in DEA’s Pharmacist’s Manual and 21 CFR Part 1301.

Ordering and receiving

For each distribution of Schedule I or II substances, a completed DEA Form 222 or an electronic order through the Controlled Substance Ordering System (CSOS) is generally required. CSOS orders are digitally signed and replace the paper form for electronic orders.

A Form 222 is not ordinarily required for Schedules III–V. Retain invoices, packing slips, or equivalent records identifying the substance, dosage form and strength, quantity, date received, and supplier information.

At receipt, compare the shipment with the order and receiving documents. Investigate discrepancies promptly, document their resolution, and ensure the records show the actual quantity received. A Form 222 or CSOS order is part of the required order record for applicable Schedule I–II transfers; it does not replace appropriate receiving and inventory controls.

For example, a pharmacy ordering Schedule II tablets may use a paper Form 222 or CSOS. For a Schedule III–V shipment, it ordinarily retains the invoice or packing slip and records the receipt in its controlled-substance records.

Inventory requirements

Take a complete, accurate initial inventory when the pharmacy first begins handling controlled substances. Record a zero inventory if there is no stock. After that, take a new inventory at least every two years; DEA does not require routine submission of the inventory. Record the inventory date and whether the count was made at the beginning or close of business.

Count all controlled substances on hand or under the pharmacy’s control, including relevant returned, damaged, or otherwise segregated stock. Inventory a newly scheduled substance in the pharmacy’s possession when the scheduling rule takes effect.

A practical inventory identifies each drug and finished form and records its quantity. Distinguish tablet strengths and dosage forms rather than recording only a drug’s general name. Routine cycle counts or a perpetual inventory can help detect discrepancies, but do not replace the federally required initial and biennial inventories.

Records and retention

Maintain complete, accurate, current records for controlled substances received, dispensed, transferred, or otherwise disposed of. Required records generally must be kept for at least two years and be available for inspection by authorized DEA officials. Maintain records for each registered location.

For a pharmacy, Schedule II inventories and records must be kept separately from other pharmacy records. Schedule III–V inventories and records may be kept separately or in a format that makes them readily retrievable. Schedule II paper prescriptions are kept in a separate file; Schedule III–V paper prescriptions may be filed separately or made readily retrievable. Electronic prescription records must meet applicable DEA requirements and be retrievable at the registered location.

A useful operational practice is to reconcile receipts, dispensing records, transfers, returns, and physical counts at defined intervals. If a count does not match the records, investigate and document the discrepancy rather than adjusting the balance without explanation.

Security and access

DEA rules require controlled substances to be stored in a securely locked, substantially constructed cabinet. Pharmacies may instead disperse Schedule II–V stock throughout noncontrolled stock in a way that obstructs theft or diversion.

Restrict access to authorized personnel. Controlled keys or access credentials, staff training, and prompt review of unexplained variances are examples of procedures that support security.

Theft and significant loss

When a theft or significant loss is discovered, notify the local DEA Field Division Office in writing within one business day. Submit DEA Form 106 through DEA’s secure reporting system within 45 days after discovery. Assess the circumstances and document the investigation; not every small discrepancy is automatically a significant loss. State and local reporting obligations may also apply.

Recalls

For a recall, promptly identify affected products and lots, stop dispensing affected stock, segregate or quarantine it, and follow the recall notice’s instructions. Keep records of affected quantities, actions taken, and disposition. FDA oversees recall strategy and effectiveness; recall details may be voluntary or FDA-requested. A recall does not remove the need to preserve controlled-substance accountability.

Returns and disposal

For unwanted controlled-substance inventory, a pharmacy may use a DEA-registered reverse distributor, arrange an authorized return or recall transfer, or destroy stock on site under DEA rules. Destruction must render the substance non-retrievable and comply with applicable environmental and other laws.

Schedule II transfers to a reverse distributor generally require the applicable Form 222 or electronic order; document Schedule III–V transfers as required. When the registrant destroys its own inventory, it generally documents the destruction on DEA Form 41. When stock is transferred to a reverse distributor, retain the transfer records and follow the rules applicable to that transfer. Do not send controlled substances to DEA unless DEA has specifically authorized it.

Pharmacy stock and patient take-back drugs are distinct. A pharmacy may collect controlled substances from ultimate users only if authorized as a DEA collector and must follow separate collection and disposal rules. Ordinary pharmacy inventory-disposal procedures do not by themselves authorize accepting patient medications.